Astrazeneca annual working capital
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Working Capital Growth & History (AZN)
Astrazeneca's working capital was −$1.89B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$1.89B | $145.0M | — |
| 2024 | 2024-12-31 | −$2.04B | $3.45B | — |
| 2023 | 2023-12-31 | −$5.49B | −$1.79B | — |
| 2022 | 2022-12-31 | −$3.70B | −$7.35B | — |
| 2021 | 2021-12-31 | $3.65B | $4.41B | — |
| 2020 | 2020-12-31 | −$763.0M | $1.79B | — |
| 2019 | 2019-12-31 | −$2.55B | −$1.85B | — |
| 2018 | 2018-12-31 | −$701.0M | $2.53B | — |
| 2017 | 2017-12-31 | −$3.23B | −$1.24B | — |
| 2016 | 2016-12-31 | −$1.99B | −$3.13B | — |
| 2015 | 2015-12-31 | $1.14B | — | — |
Astrazeneca quarterly working capital
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.59B | $1.01B | — |
| Q1 2026 | 2026-03-31 | −$2.96B | — | — |
| Q4 2025 | 2025-12-31 | −$1.89B | $145.0M | — |
| Q3 2025 | 2025-09-30 | −$4.11B | — | — |
| Q2 2025 | 2025-06-30 | −$4.60B | −$1.42B | — |
| Q4 2024 | 2024-12-31 | −$2.04B | $3.45B | — |
| Q2 2024 | 2024-06-30 | −$3.17B | $363.0M | — |
| Q4 2023 | 2023-12-31 | −$5.49B | −$1.79B | — |
| Q2 2023 | 2023-06-30 | −$3.54B | −$2.64B | — |
| Q4 2022 | 2022-12-31 | −$3.70B | −$7.35B | — |
| Q2 2022 | 2022-06-30 | −$898.0M | −$5.95B | — |
| Q4 2021 | 2021-12-31 | $3.65B | $4.41B | — |
| Q2 2021 | 2021-06-30 | $5.05B | $8.30B | — |
| Q4 2020 | 2020-12-31 | −$763.0M | $1.79B | — |
| Q2 2020 | 2020-06-30 | −$3.25B | −$2.44B | — |
| Q4 2019 | 2019-12-31 | −$2.55B | −$1.85B | — |
| Q2 2019 | 2019-06-30 | −$815.0M | $3.94B | — |
| Q4 2018 | 2018-12-31 | −$701.0M | $2.53B | — |
| Q2 2018 | 2018-06-30 | −$4.75B | — | — |
| Q4 2017 | 2017-12-31 | −$3.23B | — | — |
Astrazeneca working capital trends
Over the last five fiscal years, Astrazeneca's working capital decreased from −$763.0M to −$1.89B, a change of −$1.13B. The latest reported quarter, Q2 2026, shows −$3.59B.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...